Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | TYK2 | P29597 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | MARK3 | P27448 | 2/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10213929 | 0.89 | JAK2 (0.81) | JAK2JAK3TYK2PLK4DAPK3 | |
| SCHEMBL3359710 | 0.86 | FGFR1 (0.72) | JAK2FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL10130802 | 0.85 | JAK2 (0.60) | JAK2FGFR1FGFR2JAK3TYK2 | |
| SCHEMBL10213901 | 0.85 | JAK2 (0.71) | JAK2JAK3TYK2PLK4DAPK3 | |
| SCHEMBL12907246 | 0.84 | JAK2 (1.00) | JAK2JAK3TYK2PLK4DAPK3 | |
| SCHEMBL3359889 | 0.84 | JAK2 (1.00) | JAK2JAK3TYK2PLK4DAPK3 | |
| Hydrochloric Acid SCHEMBL10369298 | 0.83 | JAK2 (0.58) | JAK2FGFR1FGFR2JAK3TYK2 | |
| SCHEMBL12907187 | 0.82 | JAK2 (0.72) | JAK2JAK3TYK2PLK4DAPK3 | |
| SCHEMBL12907171 | 0.82 | JAK2 (0.72) | JAK2FGFR1JAK3TYK2PLK4 | |
| SCHEMBL31690865 | 0.82 | JAK2 (1.00) | JAK2JAK3TYK2PLK4DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1765788-B1 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885FGFR1 524/4885FGFR2 1415/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885FGFR1 524/4885FGFR2 1415/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | JAK2 562/4885FGFR1 868/4885FGFR2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.